Suppr超能文献

通过床旁超声对冠状病毒病-19(COVID-19)患者心脏变化进行无创评估。

Noninvasive assessment of cardiac changes in patients with coronavirus disease-19 (COVID-19) by bedside ultrasound.

作者信息

Gao Ziqing, Huang Yongquan, Lu Wuzhu, Chen Xiaobo, Li Xuefeng, Zhang Shushan, Su Zhongzhen

机构信息

Department of Ultrasound, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.

Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.

出版信息

J Thorac Dis. 2022 Feb;14(2):423-430. doi: 10.21037/jtd-21-1961.

Abstract

BACKGROUND

Patients with coronavirus disease-19 (COVID-19) are susceptible to cardiac complications, and cardiac ultrasound is the preferred noninvasive method for clinical cardiac structure and function assessment.

METHODS

We performed a retrospective study of 34 patients with COVID-19 and analyzed their clinical data, biochemistry test results [creatine kinase-MB (CK-MB), cardiac troponin I (cTnI) and C-reactive protein (CRP)], and parameters of cardiac ultrasound [left atrium (LA), left ventricular end-diastolic dimensions (LVDD), right atrium (RA), right ventricle (RV), main pulmonary artery (MPA), left ventricular ejection fraction (LVEF), tricuspid valve (TV), pulmonic valve (PV) and pulmonary artery systolic pressure (PASP)]. We classified the patients based on their clinical symptoms (mild, moderate, severe, and critical groups), and compared the parameters. CK-MB and cardiac ultrasound parameters are presented as mean ± standard deviation and compared using the one-way ANOVA. CTnI is presented as counts (percentages) and compared using the χ test, CRP is presented as [M (P, P)] [median (interquartile range)] and compared using nonparametric tests (Kruskal-Wallis test).

RESULTS

As the disease progressed, the parameters of both biochemical blood tests and cardiac ultrasound changed regularly, manifested as enlargement of the LA, LVDD, RA, RV, and MPA and increased PASP, CRP, CK-MB, and cTnI. Of these parameters, CRP, LA, LVDD, MPA, and PASP of the severe group were more notably elevated than in the mild and moderate groups (P<0.05). The critical group more showed markedly increased CK-MB, cTnI, and RA than the other groups (P<0.05), and CRP, LA, LVDD, RV, MPA, and PASP rose more sharply than in the mild and moderate groups (P<0.05).

CONCLUSIONS

As COVID-19 progressed, patients developed an enlarged heart with expanded pulmonary arteries and elevated PASP. Bedside ultrasound can be used as a noninvasive assessment of these changes and for guidance of clinical treatment.

摘要

背景

新型冠状病毒肺炎(COVID-19)患者易发生心脏并发症,心脏超声是临床评估心脏结构和功能的首选无创方法。

方法

我们对34例COVID-19患者进行了回顾性研究,分析了他们的临床资料、生化检测结果[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)和C反应蛋白(CRP)]以及心脏超声参数[左心房(LA)、左心室舒张末期内径(LVDD)、右心房(RA)、右心室(RV)、主肺动脉(MPA)、左心室射血分数(LVEF)、三尖瓣(TV)、肺动脉瓣(PV)和肺动脉收缩压(PASP)]。我们根据患者的临床症状将其分类(轻度、中度、重度和危重症组),并比较各项参数。CK-MB和心脏超声参数以均值±标准差表示,采用单因素方差分析进行比较。CTnI以计数(百分比)表示,采用χ检验进行比较,CRP以[M(P,P)][中位数(四分位间距)]表示,采用非参数检验(Kruskal-Wallis检验)进行比较。

结果

随着疾病进展,血液生化检测和心脏超声的参数均有规律地变化,表现为LA、LVDD、RA、RV和MPA增大,PASP、CRP、CK-MB和cTnI升高。在这些参数中,重度组的CRP、LA、LVDD、MPA和PASP较轻度和中度组显著升高(P<0.05)。危重症组的CK-MB、cTnI和RA较其他组明显升高(P<0.05),CRP、LA、LVDD、RV、MPA和PASP较轻度和中度组上升更为明显(P<0.05)。

结论

随着COVID-19病情进展,患者出现心脏扩大伴肺动脉扩张和PASP升高。床旁超声可用于对这些变化进行无创评估并指导临床治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca7e/8902119/34c8bd2b0984/jtd-14-02-423-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验